Tag Archives: AASLD 2017

AASLD 2017: Generics shown to be bioequivalent to originator brands

Just out of embargo for AASLD 2017 is the rather innocuous sounding Abstract 1078 which says, in brief, that these generic DAAs are inarguably proven the same as the originator DAAs. Bioequivalent pharmacokinetics for generic and originator Hepatitis C Direct Acting Antivirals Andrew M. Hill1, Loai Tahat2, Mohammed Khalil Mohammed3, Sanjay Nath4, Rabab Fayez Tayyem3, James […]

× Chat